Beam Therapeutics (BEAM) Current Leases (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Current Leases data on file, last reported at $14.8 million in Q1 2026.

• Current Leases for Q1 2026 came in at $14.8 million, up 11.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.8 million (up 11.89% YoY), and the FY2025 annual result was $14.4 million, up 6.64% from the prior year.
• Current Leases rose to $14.8 million in Q1 2026 per BEAM's latest filing, from $14.4 million in the prior quarter.
• Over five years, Current Leases peaked at $14.8 million in Q1 2026 and troughed at $1.4 million in Q1 2023.
• A 5-year average of $11.1 million and a median of $12.6 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2024: Current Leases slumped 84.82% in 2023, then surged 757.21% in 2024.
• A 5-year view of Current Leases shows it stood at $10.4 million in 2022, then gained by 23.1% to $12.8 million in 2023, then grew by 5.41% to $13.5 million in 2024, then rose by 6.64% to $14.4 million in 2025, then advanced by 2.9% to $14.8 million in 2026.
• Business Quant data shows BEAM's Current Leases at $14.8 million in Q1 2026, $14.4 million in Q4 2025, and $12.7 million in Q3 2025.